Maiti, A., DiNardo, C. D., Wang, S. A., Jorgensen, J., Kadia, T. M., Daver, N. G., . . . Ravandi, F. (2021). Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia. Blood Adv.
Chicago Style citaatMaiti, Abhishek, et al. "Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia." Blood Adv 2021.
MLA citatieMaiti, Abhishek, et al. "Prognostic Value of Measurable Residual Disease After Venetoclax and Decitabine in Acute Myeloid Leukemia." Blood Adv 2021.
Let op: Deze citaties zijn niet altijd 100% accuraat.